8-K current report · filed Sep 8, 2026

Inhibikase Therapeutics, Inc. (IKT) 8-K Current Report: September 8, 2026

Item EX-99.1Item 7.01IKT overview

Short answer

Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on September 8, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Updated corporate presentation for investor and analyst meetings.

Inhibikase Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation for investor and analyst meetings
  • Presentation materials furnished as Exhibit 99.1
  • Potentially relevant for updated pipeline, development priorities, and corporate messaging

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 IMPROVE-PAH enrolling across 26 countries and 46 of 180 planned sites, validating late-stage execution
  • IKT-001 targets PAH, a disease with approximately 30% five-year mortality and an estimated $8.3B antiproliferative market
  • Prior imatinib data showed 45-meter placebo-adjusted 6MWD improvement at higher dosing and a 32% PVR reduction
  • Twelve-week titration and prodrug design target imatinib’s GI tolerability and discontinuation limitations
  • Key catalysts: interim safety readout in 1H 2027, PVR data in mid-2028, and 6MWD topline data in mid-2029

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inhibikase Therapeutics, Inc. 8-K filings

Get the next IKT 8-K as it lands

Follow IKT for push alerts, or ask the research agent what this filing means.